Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Microbial peptidoglycan biosynthesis enzymes encompass a class of bacterial enzymes responsible for forming and remodeling peptidoglycan—the essential structural polymer in the cell wall. These enzymes include glycosyltransferases, transpeptidases, ligases (Mur ligases), and hydrolases (autolysins), each contributing specific steps from precursor assembly to polymerization and cross-linking. The pathway is highly conserved in bacteria but absent in mammalian cells, making these enzymes prime targets for antibiotics such as beta-lactams, glycopeptides, and fosfomycin, which disrupt peptidoglycan integrity and result in bacterial cell death. Drug resistance and specificity of antimicrobial agents remain central clinical challenges in the therapeutic targeting of this system.
Inhibition of transpeptidation by binding transpeptidases (PBPs), blocking cross-linking (beta-lactams) - Inhibition of glycosyltransferases, blocking glycan chain elongation (vancomycin, telavancin) - Inhibition of precursor synthesis (e.g., MurA by fosfomycin, Mur ligases by D-cycloserine) - Inhibition of lipid cycle (bacitracin)
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microbial peptidoglycan biosynthesis enzyme (null).